US Patent

US11944627 — Methods for treating hematological malignancies and Ewing's sarcoma

Method of Use · Assigned to Kura Oncology Inc · Expires 2038-09-06 · 12y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for treating hematological malignancies and Ewing's sarcoma using menin inhibitors.

USPTO Abstract

The present disclosure provides methods for treating hematological malignancies and Ewings sarcoma using menin inhibitors. Compositions for use in these methods are also provided.

Drugs covered by this patent

Komzifti (ZIFTOMENIB) · Kura

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4347`	—	Komzifti

Patent Metadata

Patent number: US11944627
Jurisdiction: US
Classification: Method of Use
Expires: 2038-09-06
Drug substance claim: No
Drug product claim: No
Assignee: Kura Oncology Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.